Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YRJDY
ADC Name	ALT-P7
Synonyms	ALT P7; HM2-MMAE; HM2-drug conjugate Click to Show/Hide
Organization	Alteogen, Inc.; Shenyang Sunshine Pharmaceutical Co., Ltd.
Drug Status	Phase 1
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Phase 1 Gastric cancer [ICD11:2B72] Phase 1
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Undisclosed
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	Undisclosed
Drugbank ID	DB17220

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT03281824	Phase 1	Open-label, dose increase and phase 1 study of ALT-P7 to determine safety, tolerability, pharmacokinetics for HER2 positive metastatic breast cancer patients who have progressed on previous trastuzumab-based therapy. Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	13.3% (4.2 mg/kg)
Patients Enrolled	Patients with HER2-positive advanced breast cancer progressive to at least two kinds of prior anti-HER2 treatment.
Administration Dosage	0.30-4.80 mg/kg iv administered once every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT03281824	Clinical Status	Phase 1
Clinical Description	Open-label, dose increase and phase 1 study of ALT-P7 to determine safety, tolerability, pharmacokinetics for HER2 positive metastatic breast cancer patients who have progressed on previous trastuzumab-based therapy.

References

Ref 1	A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma. Blood (2021) 138 (Supplement 1): 4763.